Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!

An Open-Label Study to Evaluate DPCP Ointment for the Treatment of Alopecia Areata

Study type: Clinical Trials Last updated: 02/21/2023 Status: Recruiting Country: United States Eligibility:

Age 18+; diagnosed with extensive alopecia areata

Drug: Diphenylcyclopropenone (DPCP) Ointment Administration: Topical Sponsor: University of Minnesota link: Click here Location: Minneapolis, MN


A research study is looking for adults with extensive alopecia areata. The study will assess the safety, effectiveness, and response characteristics of treatment with DPCP ointment. DPCP causes an immune response that helps treat alopecia areata.

You may qualify to participate if you:

  • are age 18 years or older;
  • have been diagnosed with alopecia areata and have 76-99% scalp hair loss
  • are willing to stop using other types of medications to treat your hair loss;
  • are willing to make a minimum of forty-two (42) visits to the study site (up to 46) over a course of approximately five to six months.

The following trial site may be contacted for more information about participation:
University of Minnesota
Department of Dermatology
Minneapolis, MN
Phone: 612-624-5721